Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (13)

2023

  1. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

    Med, Vol. 4, Núm. 10, pp. 710-727.e5

  2. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

    Nature communications, Vol. 14, Núm. 1, pp. 1359

2022

  1. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  2. Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs)

    European Journal of Cancer, Vol. 174, pp. S70

  3. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

    Neuro-Oncology Advances, Vol. 4, Núm. 1

2021

  1. First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676

  2. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

    European Journal of Cancer, Vol. 155, pp. 168-178

2020

  1. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria

    Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855

  2. Development of pharmacodynamic biomarkers for phase I trials

    Phase I Oncology Drug Development (Springer International Publishing), pp. 139-158

  3. Global gene expression characterization of circulating tumor cells in metastasic castration-resistant prostate cancer patients

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-14

  4. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

    Annals of Oncology, Vol. 31, Núm. 6, pp. 780-788

2017

  1. Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients

    Oncotarget, Vol. 8, Núm. 33, pp. 54708-54721

2012

  1. A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

    Journal of Cellular and Molecular Medicine, Vol. 16, Núm. 10, pp. 2342-2349